Clindamycin Phosphate Market

Clindamycin Phosphate Market: Introduction

• Clindamycin is an antibiotic, which works by stopping the growth of bacteria. This medication is used to treat acne. It helps to decrease the number of acne lesions. Acne is the most common skin condition that affects late adolescents globally. Acne vulgaris is a common adolescent health problem that has a significant impact on their quality of life. According to Gen Consulting Company, the global clindamycin phosphate market is projected to expand at a CAGR of 4.08% between 2020 and 2026. Significant potential of clindamycin phosphate in the infection industry is anticipated to boost the growth of the global clindamycin phosphate market.

Global Clindamycin Phosphate Market: Key Trends

• Global economic slowdown has had a significant effect on the global clindamycin phosphate injection industry. However, the industry has maintained a relatively optimistic growth rate in the past four years. According to BisReport analysts, the global clindamycin phosphate market is expected to grow at a rapid pace in the next few years.
• Most dermatologists prescribe clindamycin phosphate for the treatment of acne vulgaris. Hence, the prescription drug segment is likely to dominate the global market during the forecast period.
• In terms of gender, the global clindamycin phosphate market can be bifurcated into male and female. The female segment is projected to dominate the global market during the forecast period due to rise in prevalence of conditions, such as polycystic ovary syndrome (PCOS) and hormonal imbalances, which cause acne. 
• Clindamycin was added to the WHO's list of essential medicines in April 2013
• Clindamycin phosphate 2% is being examined as a one-time vaginal administration treatment for bacterial vaginosis (BV). The global clindamycin phosphate market is expected to expand at a significant CAGR during the forecast period (2021–2031). Rise in prevalence of bacterial vaginosis among women across the world and increase in demand for over-the-counter (OTC) products fuel the growth of the global market in the next few years. It is a vaginal disorder characterized by vaginal discharge caused by an overgrowth of certain types of bacteria in the vagina. BV is a global concern because of the increased risk of acquiring sexually transmitted infections. BV can affect people of any age, but it is more common in women of reproductive age.
• According to the American Sexual Health Association (2019), BV is a common gynecologic infection that affects nearly 29% of women in the U.S. It affects at least 15% of the sexually active population, making it three to four times more common than urinary tract infections (UTI). Rise in prevalence of BV has induced private manufacturers and research organizations to increase investment in R&D for its treatment. Several clinical trials are currently underway to expand the potential of bacterial vaginosis drugs.

North America to Capture Major Share of Global Clindamycin Phosphate Market:

• High prevalence of acne and skin diseases in the U.S. drives the clindamycin phosphate market in North America during the forecast period. Acne vulgaris is a common skin condition affecting over 50 million people in the U.S. Improper diet, excessive fast-food consumption, and excessive use of chemical-based cosmetics contribute to the rise in number of acne cases in the country.

Key Players Operating in Global Clindamycin Phosphate Market:

Major players operating in the global clindamycin phosphate market are listed below:

• Pfizer
• Perrigo
• Mylan
• Ortho Dermatologics
• Taro Pharmaceutical
• Akorn
• Teligent
• Zydus Pharmaceuticals
• North China Pharmaceutical Group

Global Clindamycin Phosphate Market: Research Scope

Global Clindamycin Phosphate Market, by Type

• Gel
• Topical Solution
• Foam
• Injections

Global Clindamycin Phosphate Market, by Gender

• Male
• Female

Global Clindamycin Phosphate Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa